Sign in

Private company

CHEMBIO DIAGNOSTICS, INC.

CHEMBIO DIAGNOSTICS, INC. is an American pharmaceutical preparations company, incorporated in Nevada.1 It is headquartered in Hauppauge, New York.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersHauppauge, New York1
  • Incorporated inNV2
  • Business address555 Wireless Blvd., Hauppauge, Ny 117882
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-47.7%Operating margin3
-47.0%Net margin3
3.6%Revenue growth, 20223
-130.9%Return on equity3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue55¢$38.6M
  • Research and development10¢$7.1M
  • Selling, general and admin35¢$24.3M
  • Income tax0¢$34.4K

Out of $49.5M in revenue.3 The company lost money this year.

Financial statements

Revenue456783$49.5M in 2022+177% since 2016
0$20.0M$40.0M$60.0M2016: $17.9M$17.9M20162017: $25.2M$25.2M2017+41%2018: $34.6M$34.6M2018+37%2019: $34.5M$34.5M2019−0%2020: $32.5M$32.5M2020−6%2021: $47.8M$47.8M2021+47%2022: $49.5M$49.5M2022+4%
Operating income4106783-$23.6M in 2022+212% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$7.6M-$7.6M20162017: -$6.5M-$6.5M2017−14%2018: -$8.0M-$8.0M2018+23%2019: -$13.3M-$13.3M2019+67%2020: -$23.1M-$23.1M2020+74%2021: -$31.1M-$31.1M2021+34%2022: -$23.6M-$23.6M2022−24%
Net income4106783-$23.3M in 2022+75% since 2016
-$40.0M-$30.0M-$20.0M-$10.0M02016: -$13.3M-$13.3M20162017: -$6.4M-$6.4M2017−52%2018: -$7.9M-$7.9M2018+23%2019: -$13.7M-$13.7M2019+74%2020: -$25.5M-$25.5M2020+87%2021: -$33.9M-$33.9M2021+33%2022: -$23.3M-$23.3M2022−31%
Fiscal year2016201720182019202020212022
Revenue$17.9M4$25.2M5$34.6M6$34.5M7$32.5M8$47.8M3$49.5M3
Cost of revenue$9.4M4$14.1M5$22.6M6$22.4M7$23.9M8$34.5M3$38.6M3
Gross profit$8.5M9
Research and development$8.4M4$8.6M10$8.5M6$8.5M7$9.5M8$12.5M3$7.1M3
Selling, general and admin$7.6M4$9.0M10$11.1M6$16.1M7$21.0M8$24.8M3$24.3M3
Operating expenses$78.9M3$73.2M3
Operating income-$7.6M4-$6.5M10-$8.0M6-$13.3M7-$23.1M8-$31.1M3-$23.6M3
Interest$04$2.9K4
Income before tax-$34.0M3-$23.3M3
Income tax$5.8M4-$88.3K10-$67.5K6-$500.3K7-$456.8K8-$62.0K3$34.4K3
Net income-$13.3M4-$6.4M10-$7.9M6-$13.7M7-$25.5M8-$33.9M3-$23.3M3
Earnings per share-$1.264-$0.5210-$0.546-$0.816-$1.348-$1.403-$0.723
Earnings per share (diluted)-$1.264-$0.5210-$0.546-$0.816-$1.348-$1.403-$0.723
Shares (weighted, basic)24.3M shares332.3M shares3
Shares (weighted, diluted)24.3M shares332.3M shares3

Compare CHEMBIO DIAGNOSTICS, INC. with another company

Corporate structure

CHEMBIO DIAGNOSTICS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CHEMBIO DIAGNOSTICS, INC.

  • PERCEPTIVE ADVISORS LLC Filed SC 13D/A on CHEMBIO DIAGNOSTICS, INC., latest May 4, 2023 (3 filings since Apr 7, 2023)
  • Biosynex SA Filed SC 13D on CHEMBIO DIAGNOSTICS, INC., latest May 1, 2023
  • VANGUARD GROUP INC Filed SC 13G/A on CHEMBIO DIAGNOSTICS, INC., latest Feb 9, 2022
  • CHEMBIO DIAGNOSTICS, INC. Hauppauge, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CHEMBIO DIAGNOSTICS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$20.3M3 Dec 31, 2022$18.9M3 Dec 31, 2021+7.7%
Accumulated depreciation$12.2M3 Dec 31, 2022$10.3M3 Dec 31, 2021+18.0%
Property and equipment, net$8.2M3 Dec 31, 2022$8.6M3 Dec 31, 2021−4.7%
Finance-lease assets$137.0K3 Dec 31, 2022$191.9K3 Dec 31, 2021−28.6%
Operating-lease assets (leased space)$5.4M3 Dec 31, 2022$5.9M3 Dec 31, 2021−7.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$18.2M3 Dec 31, 2022$28.8M3 Dec 31, 2021−36.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$03 Dec 31, 2022$3.0M3 Dec 31, 2021−100.0%
Finite-lived intangibles, gross$03 Dec 31, 2022$4.9M3 Dec 31, 2021−100.0%
Accumulated amortization$03 Dec 31, 2022$1.9M3 Dec 31, 2021−100.0%
Finite-lived intangibles, net$03 Dec 31, 2022$03 Dec 31, 2021

Inventory

ItemLatestA year beforeChange
Inventory, total$7.7M3 Dec 31, 2022$12.9M3 Dec 31, 2021−40.3%
Raw materials$4.5M3 Dec 31, 2022$7.3M3 Dec 31, 2021−37.9%
Work in process$1.1M3 Dec 31, 2022$3.6M3 Dec 31, 2021−68.9%
Finished goods$2.1M3 Dec 31, 2022$2.1M3 Dec 31, 2021+0.6%

Leadership

Who has led CHEMBIO DIAGNOSTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lawrence A. Siebert2006–2008
  2. John J. Sperzel Iii.2014–2017

Chair

  1. Lawrence A. Siebert2006–2008

President

  1. Lawrence A. Siebert2006–2014
  2. Sharon W. Klugewicz2017–2018

Chief financial officer

  1. Richard J. Larkin2006–2017
  2. Neil A. Goldman2017–2018

Chief operating officer

  1. Sharon W. Klugewicz2013–2016
2010201520202025
Board members and other officers (30)

Former names

  • Chembio Diagnostics Inc.Jun 4, 2004 to May 11, 20052
  • TRADING SOLUTIONS COM INCOct 6, 1999 to Jun 7, 20042

Timeline

  1. Apr 27, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer50
  2. Apr 6, 20238-K Listing notice or transfer51
  3. Mar 21, 20238-K Other events52
  4. Mar 15, 20238-K Other events53
  5. Feb 24, 20238-K Other events54
  6. Jan 31, 20238-K Entered a material agreement; Other events55
  7. Nov 4, 20228-K Results of operations; Regulation FD disclosure56
  8. Oct 4, 20228-K Listing notice or transfer57
  9. Sep 7, 20228-K Other events58
  10. Aug 4, 20228-K Results of operations59
  11. May 26, 20228-K Shareholder vote60
  12. May 5, 20228-K Results of operations61
  13. Mar 17, 2014New chief executive John J. Sperzel Iii. becomes CEO13
  14. Apr 19, 2006New chief executive Lawrence A. Siebert becomes CEO14

Calendar

When it reported results

  1. Nov 4, 2022Reported quarterly or annual results56
  2. Aug 4, 2022Reported quarterly or annual results59
  3. May 5, 2022Reported quarterly or annual results61
  4. Mar 3, 2022Reported quarterly or annual results62
  5. Nov 4, 2021Reported quarterly or annual results63

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

111 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 23 major events, 30 insider forms, 5 large holders, 47 other. The latest 20:

  1. May 9, 202315-12G EDGAR
  2. May 4, 2023SC 13D/A EDGAR
  3. May 2, 2023EFFECT EDGAR
  4. May 2, 2023EFFECT EDGAR
  5. May 2, 2023EFFECT EDGAR
  6. May 2, 2023EFFECT EDGAR
  7. May 2, 2023EFFECT EDGAR
  8. May 2, 20234 EDGAR
  9. May 1, 20234 EDGAR
  10. May 1, 20234 EDGAR
  11. May 1, 20234 EDGAR
  12. May 1, 20234 EDGAR
  13. May 1, 20234 EDGAR
  14. May 1, 20234 EDGAR
  15. May 1, 20234 EDGAR
  16. May 1, 20234 EDGAR
  17. May 1, 20234 EDGAR
  18. May 1, 2023SC 13D EDGAR
  19. May 1, 20234 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
  20. Apr 27, 202325-NSE EDGAR

The 111 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 13 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 25, 2023EDELMAN JOSEPHBuy133,742$0.45$60.2KForm 4
Apr 24, 2023EDELMAN JOSEPHBuy39,506$0.45$17.8KForm 4
Apr 21, 2023EDELMAN JOSEPHBuy70,200$0.45$31.6KForm 4
Apr 20, 2023Perceptive Credit Advisors, LLCBuy56,000$0.45$25.2KForm 4
Apr 19, 2023Perceptive Credit Advisors, LLCBuy137,000$0.45$61.6KForm 4
Apr 18, 2023Perceptive Credit Advisors, LLCBuy15,800$0.45$7.1KForm 4
Apr 17, 2023Perceptive Credit Advisors, LLCBuy4,800$0.45$2.2KForm 4
Apr 14, 2023Perceptive Credit Advisors, LLCBuy11,500$0.45$5.2KForm 4
Apr 13, 2023Perceptive Credit Advisors, LLCBuy140,134$0.45$63.1KForm 4
Apr 11, 2023Perceptive Credit Advisors, LLCBuy129,000$0.44$56.8KForm 4
Apr 6, 2023PERCEPTIVE ADVISORS LLCBuy339,000$0.44$149.2KForm 4
Apr 5, 2023PERCEPTIVE ADVISORS LLCBuy217,500$0.45$97.9KForm 4
Apr 4, 2023PERCEPTIVE ADVISORS LLCBuy195,938$0.44$86.2KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CHEMBIO DIAGNOSTICS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCHEMBIO DIAGNOSTICS, INC.1
  • CIK0001092662
  • Employer ID (EIN)88-04256911
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNevada1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address555 Wireless Blvd., Hauppauge, NY 117881
  • Phone(631) 924-11351
  • Shares outstanding36,725,858 as of Mar 24, 20233
  • Public float$18.7M as of Jun 30, 20223
  • On EDGAR sinceAug 23, 19991
  • Filings1,126 in all: 8-K (424), 4 (223), 10-Q (46), 3 (33), SC 13G/A (31), 10QSB (22), UPLOAD (22), CORRESP (21)1
    All 60 form types

    SC 13G (20), EFFECT (19), 424B3 (18), DEF 14A (18), POS AM (18), 8-K/A (17), 10-K (15), 424B5 (14), SC 13D/A (14), SB-2/A (13), SC 14D9/A (10), 10KSB (9), SC TO-T/A (9), SC 13D (7), S-8 (6), S-8 POS (6), DEFA14A (5), NT 10-Q (5), REGDEX (5), S-3 (5), SB-2 (5), 10-K/A (4), 3/A (4), 4/A (4), 8-A12G (4), PRE 14A (4), S-3/A (4), 10QSB/A (3), 144 (3), DEFR14A (3), NT 10-K (3), S-1/A (3), 10-Q/A (2), 10KSB/A (2), AW (2), PRE 14C (2), RW (2), S-1 (2), SUPPL (2), 144/A (1), 15-12G (1), 25-NSE (1), 8-A12B (1), CERTNAS (1), DEF 14C (1), DEFR14C (1), REGDEX/A (1), SC 14D9 (1), SC 14F1 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 29, 2023
    Quarterly report (10-Q) Nov 3, 2022
    Proxy statement (DEF 14A) Apr 11, 2022
    Latest 8-K (8-K) Apr 27, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
    SEC EDGAROther events
  53. 53
    SEC EDGAROther events
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66